{"title":"人类癌症患者外周血杀伤淋巴细胞亚群OKT-3/环磷酰胺上调","authors":"C Wiseman, Y Hood, C Presant, P Kennedy","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We have initiated a clinical trial in 7 patients using low-dose OKT-3 monoclonal antibody, 50 mcg, followed 24 hours later by low-dose cyclophosphamide, 300 mg/m2. Complete data in 5 patients indicate a significant up-regulation of the number of peripheral blood lymphocytes. Before treatment, the mean (+/- standard deviation) total lymphocyte count was 524 (+/- 364)/mm3. After 4 weeks the value rose 64% to 860 (+/- 243)/mm3, (P less than .025, Student's t test). Similar changes were observed for the CD3+, CD4+, CD8+, and CD16+ (NK) lymphocyte subsets. The mean CD3+ population rose from 372 (+/- 325)/mm3 to 593 (+/- 300)/mm3 (P less than .025), the mean CD4+ group rose from 209 (+/- 142)/mm3 to 321 (+/- 104)/mm3 (P less than .05), the CD8+ cells rose from 218 (+/- 205)/mm3 to 341 (+/- 197)/mm3 (P less than .05), and the CD16+ (NK cells) rose from 80 (+/- 37)/mm3 to 157 (+/- 63)/mm3 (P less than .025). Statistically significant up-regulation occurred for all patients. The fraction of each lymphocyte subset and the T4/T8 ratio did not change. OKT-3/cyclophosphamide appears to modulate the number of circulating lymphocytes in human cancer patients.</p>","PeriodicalId":18809,"journal":{"name":"Molecular biotherapy","volume":"3 2","pages":"63-7"},"PeriodicalIF":0.0000,"publicationDate":"1991-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"OKT-3/cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients.\",\"authors\":\"C Wiseman, Y Hood, C Presant, P Kennedy\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We have initiated a clinical trial in 7 patients using low-dose OKT-3 monoclonal antibody, 50 mcg, followed 24 hours later by low-dose cyclophosphamide, 300 mg/m2. Complete data in 5 patients indicate a significant up-regulation of the number of peripheral blood lymphocytes. Before treatment, the mean (+/- standard deviation) total lymphocyte count was 524 (+/- 364)/mm3. After 4 weeks the value rose 64% to 860 (+/- 243)/mm3, (P less than .025, Student's t test). Similar changes were observed for the CD3+, CD4+, CD8+, and CD16+ (NK) lymphocyte subsets. The mean CD3+ population rose from 372 (+/- 325)/mm3 to 593 (+/- 300)/mm3 (P less than .025), the mean CD4+ group rose from 209 (+/- 142)/mm3 to 321 (+/- 104)/mm3 (P less than .05), the CD8+ cells rose from 218 (+/- 205)/mm3 to 341 (+/- 197)/mm3 (P less than .05), and the CD16+ (NK cells) rose from 80 (+/- 37)/mm3 to 157 (+/- 63)/mm3 (P less than .025). Statistically significant up-regulation occurred for all patients. The fraction of each lymphocyte subset and the T4/T8 ratio did not change. OKT-3/cyclophosphamide appears to modulate the number of circulating lymphocytes in human cancer patients.</p>\",\"PeriodicalId\":18809,\"journal\":{\"name\":\"Molecular biotherapy\",\"volume\":\"3 2\",\"pages\":\"63-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular biotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
OKT-3/cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients.
We have initiated a clinical trial in 7 patients using low-dose OKT-3 monoclonal antibody, 50 mcg, followed 24 hours later by low-dose cyclophosphamide, 300 mg/m2. Complete data in 5 patients indicate a significant up-regulation of the number of peripheral blood lymphocytes. Before treatment, the mean (+/- standard deviation) total lymphocyte count was 524 (+/- 364)/mm3. After 4 weeks the value rose 64% to 860 (+/- 243)/mm3, (P less than .025, Student's t test). Similar changes were observed for the CD3+, CD4+, CD8+, and CD16+ (NK) lymphocyte subsets. The mean CD3+ population rose from 372 (+/- 325)/mm3 to 593 (+/- 300)/mm3 (P less than .025), the mean CD4+ group rose from 209 (+/- 142)/mm3 to 321 (+/- 104)/mm3 (P less than .05), the CD8+ cells rose from 218 (+/- 205)/mm3 to 341 (+/- 197)/mm3 (P less than .05), and the CD16+ (NK cells) rose from 80 (+/- 37)/mm3 to 157 (+/- 63)/mm3 (P less than .025). Statistically significant up-regulation occurred for all patients. The fraction of each lymphocyte subset and the T4/T8 ratio did not change. OKT-3/cyclophosphamide appears to modulate the number of circulating lymphocytes in human cancer patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
